RSNA MIDRC Data Contribution Hits 30,000

After less than two years of data collection and processing, the Radiological Society of North America (RSNA) has successfully delivered over 30,000 de-identified imaging exams to the Medical Imaging and Data Resource Center (MIDRC), an open-access platform which publishes data to be used for research.

The RSNA contribution includes COVID-19 patient chest X-ray and CT images solicited from sites around the world. Each image dataset contains patient demographics and is accompanied by relevant clinical data points including hospital and ICU admission and discharge, as well as breathing support provided.

“RSNA is delighted to collaborate on the development of MIDRC,” said Curtis P. Langlotz, M.D., Ph.D., RSNA Board liaison for information technology and annual meeting and professor of radiology and biomedical informatics, director of the Center for Artificial Intelligence in Medicine and Imaging and associate chair for information systems in the Department of Radiology at Stanford University. “MIDRC is a massive, curated, diverse, multi-institutional imaging dataset that enables new insights about the diagnosis and prediction of COVID-19 infection, its complications and its outcomes. From the release of the first set of images to today, we are realizing the benefits of new algorithms and the resulting innovations in machine learning.”

MIDRC is funded by the National Institute of Biomedical Imaging and Bioengineering, hosted by the University of Chicago, and jointly developed by RSNA, the American College of Radiology and the American Association of Physicists in Medicine.

MIDRC organizers recently announced that funding will be available for year three. Interested institutions are encouraged to review the necessary steps to participate in this initiative.

Members of the medical community can attend MIDRC virtual seminars scheduled on the third Tuesday of every month at 2:00 p.m. CT. The seminar series offers an opportunity to hear directly from the MIDRC team and features research presentations from MIDRC investigators on new and noteworthy advances. Sessions are held online and include live Q&A for all attendees. The next seminar will take place on June 21.

For more information, visit MIDRC.org.

SourceRSNA

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”